Dignify Therapeutics is a virtual drug development company focused on restoring voluntary control of excretory function to neurologically-impaired people. We operate as a lean, efficient organization with an aggressive approach to drug development. Our relationships with key opinion leaders in urology and gastroenterology provide access to the best patient care and clinical research centers in the world. This allows a fast, flexible and state-of-the-art clinical approach that will result in delivery of desperately needed new treatments to the market.
The Company is conducting all preclinical and clinical development activities for DTI-100 and three follow-on programs through Phase II proof-of-concept studies. At that point we will consider out-licensing our programs to partners for further clinical development and commercialization. Funding for our programs involves a combination of government and foundation grants, corporate loans, and equity financing.
The Company is developing a patent portfolio that covers our lead development program, DTI-100, as well as three follow-on programs to treat bladder and bowel disorders. Dignify Therapeutics uses a “repositioning strategy” for drug discovery and clinical development (see Dr. Thor’s publication on repositioning published in Nature: Drug Discovery) . We have succesfully applied this strategy to put 2 urology drugs on the market in Europe that are the first ever therapies approved for their respective indications.Through a combination of a strong intellectual property estate and an aggressive clinical development approach, Dignify Therapeutics will deliver new treatments while building value for the Company.